Recursion Pharmaceuticals (RXRX) Competitors $5.84 +0.32 (+5.80%) Closing price 04:00 PM EasternExtended Trading$5.88 +0.04 (+0.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. BPMC, ROIV, ELAN, LEGN, RGC, RVMD, GRFS, TGTX, NUVL, and LNTHShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Its Competitors Blueprint Medicines Roivant Sciences Elanco Animal Health Legend Biotech Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Nuvalent Lantheus Blueprint Medicines (NASDAQ:BPMC) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Do analysts prefer BPMC or RXRX? Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.95%. Recursion Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 19.86%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.24Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer BPMC or RXRX? In the previous week, Blueprint Medicines had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 8 mentions for Blueprint Medicines and 1 mentions for Recursion Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.15 beat Recursion Pharmaceuticals' score of 0.81 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in BPMC or RXRX? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, BPMC or RXRX? Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M16.43-$67.09M-$2.47-52.42Recursion Pharmaceuticals$58.84M40.35-$463.66M-$1.77-3.30 Which has more risk & volatility, BPMC or RXRX? Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Is BPMC or RXRX more profitable? Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% Recursion Pharmaceuticals -961.32%-74.70%-54.02% SummaryBlueprint Medicines beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.24B$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio-3.304.4521.0120.09Price / Sales40.35709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book2.245.008.125.65Net Income-$463.66M$30.99M$3.25B$257.91M7 Day Performance10.61%1.69%0.97%2.09%1 Month Performance14.29%9.20%7.36%11.13%1 Year Performance-25.79%-1.25%31.31%18.40% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals1.1335 of 5 stars$5.84+5.8%$7.00+19.9%-33.9%$2.24B$58.84M-3.30400Gap UpHigh Trading VolumeBPMCBlueprint Medicines1.0832 of 5 stars$129.36+0.0%$128.25-0.9%+13.2%$8.35B$508.82M-52.36640News CoveragePositive NewsHigh Trading VolumeROIVRoivant Sciences2.6714 of 5 stars$11.57+1.8%$16.50+42.7%+3.6%$7.86B$29.05M-46.26860ELANElanco Animal Health1.8068 of 5 stars$14.88-0.2%$15.33+3.1%+14.6%$7.40B$4.44B20.149,000Analyst UpgradeAnalyst RevisionLEGNLegend Biotech3.5835 of 5 stars$39.81+2.2%$72.70+82.6%-23.4%$7.31B$627.24M-67.452,609News CoveragePositive NewsAnalyst ForecastAnalyst RevisionRGCRegencell Bioscience0.2214 of 5 stars$14.27-3.3%N/AN/A$7.29BN/A0.0010Gap UpRVMDRevolution Medicines4.5503 of 5 stars$38.76+1.9%$68.00+75.5%-15.9%$7.20B$11.58M-9.67250Analyst ForecastGRFSGrifols3.8994 of 5 stars$9.77+0.3%$10.30+5.5%+24.7%$6.71B$7.81B8.3523,822News CoverageTGTXTG Therapeutics3.4049 of 5 stars$38.70+4.3%$43.80+13.2%+77.5%$6.09B$329M159.75290NUVLNuvalent3.1882 of 5 stars$83.79+3.5%$119.60+42.7%+6.4%$6.01BN/A-19.0640Insider TradeLNTHLantheus4.6282 of 5 stars$82.30+1.2%$131.20+59.4%-39.5%$5.70B$1.53B23.41700News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Blueprint Medicines Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Legend Biotech Competitors Regencell Bioscience Competitors Revolution Medicines Competitors Grifols Competitors TG Therapeutics Competitors Nuvalent Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.